Startup · $1.3m raised
Perth, WA
Programs: CSIRO (ON Accelerate) · Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round Cytophenix raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon BioCatalyst | Accelerator | - |
| CSIRO | Accelerator | - |
Companies Cytophenix acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Cytophenix. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Perth medtech spin-out Cytophenix raised a pre-seed round above its target to advance trials and grow the team behind FloCAST, a rapid test identifying effective antibiotics, after earlier grants and accelerator programs.
Roundup of eight funding deals: Synchron's Series D, plus raises by Lumonus AI, Hullbot, Nbryo, Cytophenix, Giftbee, Understanding Zoe and Zeligate, spanning medtech, robotics, agtech and AI.
Also Startup Daily·Startup Daily·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily
Brandon BioCatalyst's CUREator incubator has granted an extra $1.865m across four Australian biotechs working on antibiotic prescribing, schizophrenia, muscular dystrophy and autoimmune therapies, on top of their initial awards.
CSIRO has picked twelve deep-tech teams, mostly from Australian universities, for the eighth edition of its ON Accelerate commercialisation program starting in February 2024.
Biotech incubator CUREator's second round distributes $12 million among 19 health-focused startups, supported by government funding, while a new MedTech program backed by $50 million arrives later in the year.
CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.